Sana Biotechnology’s Hypoimmune Platform: A ... - Markets Insider

Jan 8, 2025 · Additionally, the long-term potential of Sana’s hypoimmune platform to extend its application across various cell types underpins the Buy rating and high-risk designation, with a …

200%
OFF

Sana Biotech Stock Jumps On Cell Therapy Data (SANA:NASDAQ)

2 weeks from now

Jan 8, 2025 · Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell …

seekingalpha.com

$15
OFF

Citi Keeps $15 Target On Sana, Says Data ... - Markets Insider

2 weeks from now

Jan 8, 2025 · Citi says that while the wait for Sana Biotechnology’s (SANA) initial type 1 diabetes data was long, the “reward was well worth it as Sana has delivered what looks to be potentially ...

businessinsider.com

265%
OFF

Sana Biotechnology Shares Spike Following Successful …

2 weeks from now

Jan 7, 2025 · The stock more than tripled, up 265% to $6.02, in after-hours trading Tuesday. Shares ended the regular session 5.7% lower, at $1.65, putting them down 68% in the last 52 …

marketwatch.com

$12
OFF

Sana Biotechnology Price Target Raised To $12 From $9 ... - Markets …

2 weeks from now

4 days ago · Morgan Stanley raised the firm’s price target on Sana Biotechnology (SANA) to $12 from $9 and keeps an Overweight rating on the shares. Based on the recent type one diabetes …

businessinsider.com

FAQs about Sana Biotechnology’s Hypoimmune Platform: A ... - Markets Insider Coupon?

What is Sana's hypoimmune platform?

Sana’s hypoimmune platform is designed to create cells ex vivo that can “hide” from the patient’s immune system to enable the transplant of allogeneic cells without the need for immunosuppression. ...

Should you buy Sana biotechnology (Sana – research report)?

Analyst Samantha Semenkow of Citi maintained a Buy rating on Sana Biotechnology ( SANA – Research Report ), with a price target of $8.00. Samantha Semenkow has given her Buy rating due to a combination of factors related to Sana Biotechnology’s prospective clinical data and the potential validation of its hypoimmune platform technology. ...

Why did Sana biotechnology (Sana) rise 200%?

Sana Biotechnology (NASDAQ: SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according to Morgan Stanley, has de-risked the company's hypoimmune (HIP) therapeutic platform. ...

What is Sana biotechnology?

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. ...

Why did Sana biotechnology stock soared after Phase 1 data?

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has de-risked its HIP platform. Read more here. ...

Is Sana biotechnology's'reward' worth it?

Citi says that while the wait for Sana Biotechnology’s (SANA) initial type 1 diabetes data was long, the “reward was well worth it as Sana has delivered what looks to be potentially transformative data,” the analyst tells investors in a research note. ...